Early versus delayed endocrine therapy for prostate cancer

Endocrine-Related Cancer

Volumn 14, Issue 1, 2007, Pages 1-11

  Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN AGONIST; MEGESTROL ACETATE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BONE DENSITY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GYNECOMASTIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; INTERMETHOD COMPARISON; LIBIDO; LYMPH NODE METASTASIS; META ANALYSIS; MONOTHERAPY; NAUSEA; ORCHIECTOMY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; MALE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 34249823103     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0022     Document Type: Review

References (51)

1. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C et al. 2002 Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 103-106.
2. Byar DP & Corle DK 1988 Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monographs 7 165-170.
3. Collette L, de Reijke TM, Schröder FH & EORTC Genitourinary Group 2003 Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892) European Urology 44 182-189 (discussion 189).
4. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH & European Organisation for Research and Treatment of Cancer; Limburgs Universitair Centrum; AstraZeneca Pharmaceuticals 2005 Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals Journal of Clinical Oncology 23 6139-6148.
5. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A & Kantoff PW 2004 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. Journal of the American Medical Association 292 821-827.
6. Daniell HW 1997 Osteoporosis after orchiectomy for prostate cancer. Journal of Urology 157 439-444.
7. Dawson NA & McLeod DG 1995 Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. Journal of Urology 153 1946-1947.
8. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM et al. 1998 Bilateral orchiectomy with or without Flutamide for metastatic prostate cancer. New England Journal of Medicine 339 1036-1042.
9. Ellis WJ & Grayhack JT 1963 Sexual function in ageing males after orchiectomy and estrogen therapy. Journal of Urology 89 895-899.
10. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB & Gardiner RA 2002 Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and Cyproterone acetate: a randomized controlled trial. BJU International 90 427-432.
11. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB & Gardiner RA 2004 Quality of life compared during pharmacological treatments and clinical monitoring for non-localised prostate cancer: a randomised controlled trial. BJU International 93 975-979.
12. Hall R, Hedlund PO, Ackermann R, Bruchovsky N, Dalesio O, Debruyne F, Murphy GP, Parmar MK, Pavone-Macaluso M, Ruutu M et al. 1997 Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials. Urology 49 39-45.
13. Hanks GE, Lu JD, Machtay M, Venkatesan VM, Pinover WH, Byhardt RW & Rosenthal SA 2000 RTOG protocol 92-02: a phase III trial of the use of long term total androgen supression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. International Journal of Radiation Oncology, Biology and Physics 48 112.
14. Hanks GE, Pajak TF, Porter A, Grignon D, Bereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM & Shipley WH 2003 Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. Journal of Clinical Oncology 21 3972-3978.
15. Herr HW & O'Sullivan M 2000 Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. Journal of Urology 163 1743-1746.
16. Holzbeierlein JM, McLaughlin MD & Thrasher JB 2004 Complications of androgen deprivation therapy for prostate cancer. Current Opinion in Urology 14 177-183 (Review).
17. Huggins C & Hodges CV 1941 Studies on prostate cancer. I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-297.
18. Huggins C, Stevens RE & Hodges CV 1941 Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Archives of Surgery 43 209.
19. Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM et al. 2004 Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program Urology 63 928-933.
20. Keating NL, O'Malley AJ & Smith MR 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 24 4448-4456.
21. Kirk D 1997 MRC study: when to commence treatment in advanced prostate cancer. Prostate Cancer and Prostatic Disease 1 11-15.
22. Labrie F, Belanger A, Veilleux R, Lacoste D, Labile C, Marchetti B, Poulin R, Dupont A, Cusan L & Luthy I 1988 Rationale for maximal androgen withdrawal in the therapy of prostate cancer. Baillieres Clinical Oncology 2 597-619.
23. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE et al. 1994 Megestrol acetate for the prevention of hot flashes. New England Journal of Medicine 331 347-352.
24. McLeod DG, Iversen P, See WA, Morris T, Armstrong J & Wirth MP 2006 Casodex Early Prostate Cancer Trialist's Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International 97 247-254.
25. Medical Research Council Prostate Cancer Working Party Investigators Group 1997 Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. British Journal of Urology 79 235-246.
26. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED & Trump D 1999 Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New England Journal of Medicine 341 1781-1788.
27. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D & Eastern Cooperative Oncology Group study EST 2006 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncology 7 472-479.
28. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D & Resnick MI 2000 Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56 1021-1024.
29. Peto R, Dalesio O and the PCTCG group, website of the Federation of European Cancer Societies ECCO 12, Copenhagen 2004, http://supply.lanl.gov/ property/ecco/History/2004/presentations2004/default.shtml.
30. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO & Grignon D 2005 Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. International Journal of Radiation Oncology, Biology and Physics 61 1285-1290.
31. Pirl WF, Siegel GI, Goode MU & Smith MR 2002 Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 11 518-623.
32. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD & Walsh PC 1999 Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association 282 1591.
33. Prostate Cancer Trialists' Collaborative Group 2000 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 1491-1498.
34. Radlmaier A, Neumann F & Bormacher K 1989 Hot flushes: mechanism and prevention. Progress in Clinical and Biological Research 303 89.
35. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B et al. 2002 A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute 94 1458-1468.
36. Salminen EK, Portin RI, Koskinen AI, Helenius HY & Nurmi MJ 2005 Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 103 1381-1387.
37. Schröder FH, Collette L, de Reijke TM & Whelan P 2000 Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer British Journal of Cancer 82 283-290.
38. Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, Debois M, Collette L & Members of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group 2004a Early versus delayed endocrine treatment of pNl-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study. Journal of Urology 172 923-927.
39. Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven F, Debois M, Collette L & Members of the EORTC Genito-Urinary Group 2004b Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the 'European Organization for Research and Treatment of Cancer' (EORTC) Protocol 30892. European Urology 45 457-464.
40. See W, Iversen P, Wirth M, McLeod D, Garside L & Morris T 2003 Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology 44 512-517 (discussion 517-8).
41. Shahinian VB, Kuo YF, Freeman JL & Goodwin JS 2005 Risk of fracture after androgen deprivation for prostate cancer. New England Journal of Medicine 352 154-164.
42. Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA & Machtay M 2002 Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. International Journal of Radiation Oncology, Biology, Physics 54 1302-1310.
43. Smith MR 2003 Changes in body composition during hormonal therapy for prostate cancer. Clinical Prostate Cancer 2 18-21.
44. Strum SB, McDermed JE, Scholz MC, Johnson H & Tisman G 1997 Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. British Journal of Urology 79 933-941.
45. Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ, Gasser T, Senn E, Trinkler FB, Tscholl RM, Thalmann GN et al. 2004 Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. Journal of Clinical Oncology 23 936 (Erratum in: Journal of Clinical Oncology 2005 23:936).
46. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M et al. 2006 Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. Journal of Clinical Oncology 24 1868-1876.
47. Thompson IM, Zeidman EJ & Rodriguez FR 1990 Sudden death due to disease flare with luteinizing hormone-releasing agonist therapy for carcinoma of the prostate. Journal of Urology 144 1479-1480.
48. UICC International Union Against Cancer 1997 In TNM Classification of Malignant Tumours, pp 170-173. Eds LH Sobin & CH Wittekind. Wiley-Liss: New York, USA.
49. Veterans Administration Cooperative Urological Research Group (VACURG) 1967 Treatment and survival of patients with cancer of the prostate. Surgery, Gynecology and Obstetrics 124 1011-1017.
50. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K & Casodex Early Prostate Cancer Trialists' Group 2004 Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. Journal of Urology 172 1865-1870.
51. Yannucci J, Manol J, Garnick M & Bubley G. The effect of androgen deprivation therapy (ADT) on lipid and Hb parameters. Proceedings of the American Society of Clinical Oncology; May 13-17, 2005. Orlando, FL, USA, Abstract 4562.